• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Cancer Biomarkers Market 2012-2016 - Product Image

Global Cancer Biomarkers Market 2012-2016

  • ID: 2386302
  • January 2013
  • Region: Global
  • 37 pages
  • TechNavio

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.22 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Cancer Biomarkers market has also been witnessing the trend of the emergence of personalized medicines. However, the poor regulatory and reimbursement systems could pose a challenge to the growth of this market.

TechNavio's report, the Global Cancer Biomarkers market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are Abbott Laboratories, Affymetrix, Inc., Agilent Technologies Inc., Gen-Probe Inc., Hologic, Inc., and Roche Diagnostics Corp.

The other vendors mentioned in the report are Agendia BV, Ambrilia Biopharma, Astellas Pharma US Inc., Morphotek, Inc., Gen-Probe, Inc., Veridex LLC, READ MORE >

01. Executive Summary
02. Introduction
03. Market Coverage
Market Overview
04. Market Landscape
Market Size and Forecast
04.1 Five Forces Analysis
05. Geographical Segmentation
06. Rate of Incidence and Prevalence
07. Vendor Landscape
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and Their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Key Vendor Analysis
14.1 Abbott Laboratories
Business Overview
SWOT Analysis
14.2 Affymetrix Inc.
Business Overview
SWOT Analysis
14.3 Agilent Technologies Inc.
Business Overview
SWOT Analysis
14.4 Hologic Inc.
Business Overview
SWOT Analysis
14.5 Roche Diagnostics Corp.
Business Overview
SWOT Analysis
15. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Cancer Biomarkers Market 2012-2016 (US$ million)
Exhibit 2: Global Cancer Biomarkers Market by Geographical Segmentation 2012

TechNavio Announces the Publication of its Research Report - Global Cancer Biomarkers Market 2012-2016

TechNavio today launched its report, Global Cancer Biomarkers Market 2012-2016, based on an in-depth analysis covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers' understanding of the significant trends impacting this market.

Commenting on the report, an analyst from TechNavio's Healthcare team said: ''Over the years, personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. Personalized medicines are increasingly being used in targeted cancer therapies. As personalized medicines gain more importance and popularity, the demand for biomarkers is expected to increase. In the coming years, as personalized medicines become more popular, conventional approaches will automatically become obsolete.''

According to the report, over the years, the Global Cancer Biomarkers market has been experiencing an increase in support for biomarker research from various government agencies. For instance, the US Food and Drug Administration (FDA) and National Cancer Institute are taking an active interest in biomarker research because of the decreasing success rate in the discovery and development of oncology drugs. The FDA has been favoring the use of biomarkers in drug discovery research. It is expected that the FDA will provide simple and flexible regulatory norms and validation procedures for biomarkers in the coming years. This favorable regulatory environment for biomarkers is expected to have a strong impact on the growth of market during the forecast period.

Further, the report reveals that one of the key challenges is the existence of poor regulatory and reimbursement systems.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Abbott Laboratories, Affymetrix, Agilent Technologies, Gen-Probe, Hologic, Roche Diagnostics, Agendia, Ambrilia Biopharma, Astellas Pharma US, Morphotek, Gen-Probe, Veridex, Morphotek, Immunomedics, Clarient

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos